Copyright Reports & Markets. All rights reserved.

Global T Cell Surface Glycoprotein CD4 Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 T Cell Surface Glycoprotein CD4 Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global T Cell Surface Glycoprotein CD4 Market Size Growth Rate by Product
      • 1.4.2 Forigerimod Acetate
      • 1.4.3 HIV Vaccine 2
      • 1.4.4 Ibalizumab
      • 1.4.5 Others
    • 1.5 Market by End User
      • 1.5.1 Global T Cell Surface Glycoprotein CD4 Market Size Growth Rate by End User
      • 1.5.2 HIV
      • 1.5.3 AIDS
      • 1.5.4 GVHD
      • 1.5.5 SARS
      • 1.5.6 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global T Cell Surface Glycoprotein CD4 Market Size
      • 2.1.1 Global T Cell Surface Glycoprotein CD4 Revenue 2014-2025
      • 2.1.2 Global T Cell Surface Glycoprotein CD4 Sales 2014-2025
    • 2.2 T Cell Surface Glycoprotein CD4 Growth Rate by Regions
      • 2.2.1 Global T Cell Surface Glycoprotein CD4 Sales by Regions
      • 2.2.2 Global T Cell Surface Glycoprotein CD4 Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 T Cell Surface Glycoprotein CD4 Sales by Manufacturers
      • 3.1.1 T Cell Surface Glycoprotein CD4 Sales by Manufacturers
      • 3.1.2 T Cell Surface Glycoprotein CD4 Sales Market Share by Manufacturers
      • 3.1.3 Global T Cell Surface Glycoprotein CD4 Market Concentration Ratio (CR5 and HHI)
    • 3.2 T Cell Surface Glycoprotein CD4 Revenue by Manufacturers
      • 3.2.1 T Cell Surface Glycoprotein CD4 Revenue by Manufacturers (2014-2019)
      • 3.2.2 T Cell Surface Glycoprotein CD4 Revenue Share by Manufacturers (2014-2019)
    • 3.3 T Cell Surface Glycoprotein CD4 Price by Manufacturers
    • 3.4 T Cell Surface Glycoprotein CD4 Manufacturing Base Distribution, Product Types
      • 3.4.1 T Cell Surface Glycoprotein CD4 Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers T Cell Surface Glycoprotein CD4 Product Type
      • 3.4.3 Date of International Manufacturers Enter into T Cell Surface Glycoprotein CD4 Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global T Cell Surface Glycoprotein CD4 Sales by Product
    • 4.2 Global T Cell Surface Glycoprotein CD4 Revenue by Product
    • 4.3 T Cell Surface Glycoprotein CD4 Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global T Cell Surface Glycoprotein CD4 Breakdown Data by End User

    6 North America

    • 6.1 North America T Cell Surface Glycoprotein CD4 by Countries
      • 6.1.1 North America T Cell Surface Glycoprotein CD4 Sales by Countries
      • 6.1.2 North America T Cell Surface Glycoprotein CD4 Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America T Cell Surface Glycoprotein CD4 by Product
    • 6.3 North America T Cell Surface Glycoprotein CD4 by End User

    7 Europe

    • 7.1 Europe T Cell Surface Glycoprotein CD4 by Countries
      • 7.1.1 Europe T Cell Surface Glycoprotein CD4 Sales by Countries
      • 7.1.2 Europe T Cell Surface Glycoprotein CD4 Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe T Cell Surface Glycoprotein CD4 by Product
    • 7.3 Europe T Cell Surface Glycoprotein CD4 by End User

    8 Asia Pacific

    • 8.1 Asia Pacific T Cell Surface Glycoprotein CD4 by Countries
      • 8.1.1 Asia Pacific T Cell Surface Glycoprotein CD4 Sales by Countries
      • 8.1.2 Asia Pacific T Cell Surface Glycoprotein CD4 Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific T Cell Surface Glycoprotein CD4 by Product
    • 8.3 Asia Pacific T Cell Surface Glycoprotein CD4 by End User

    9 Central & South America

    • 9.1 Central & South America T Cell Surface Glycoprotein CD4 by Countries
      • 9.1.1 Central & South America T Cell Surface Glycoprotein CD4 Sales by Countries
      • 9.1.2 Central & South America T Cell Surface Glycoprotein CD4 Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America T Cell Surface Glycoprotein CD4 by Product
    • 9.3 Central & South America T Cell Surface Glycoprotein CD4 by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa T Cell Surface Glycoprotein CD4 by Countries
      • 10.1.1 Middle East and Africa T Cell Surface Glycoprotein CD4 Sales by Countries
      • 10.1.2 Middle East and Africa T Cell Surface Glycoprotein CD4 Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa T Cell Surface Glycoprotein CD4 by Product
    • 10.3 Middle East and Africa T Cell Surface Glycoprotein CD4 by End User

    11 Company Profiles

    • 11.1 Biotest AG
      • 11.1.1 Biotest AG Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Biotest AG T Cell Surface Glycoprotein CD4 Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Biotest AG T Cell Surface Glycoprotein CD4 Products Offered
      • 11.1.5 Biotest AG Recent Development
    • 11.2 Bristol-Myers Squibb Co
      • 11.2.1 Bristol-Myers Squibb Co Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Bristol-Myers Squibb Co T Cell Surface Glycoprotein CD4 Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Bristol-Myers Squibb Co T Cell Surface Glycoprotein CD4 Products Offered
      • 11.2.5 Bristol-Myers Squibb Co Recent Development
    • 11.3 CEL-SCI Corp
      • 11.3.1 CEL-SCI Corp Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 CEL-SCI Corp T Cell Surface Glycoprotein CD4 Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 CEL-SCI Corp T Cell Surface Glycoprotein CD4 Products Offered
      • 11.3.5 CEL-SCI Corp Recent Development
    • 11.4 Fountain Biopharma Inc
      • 11.4.1 Fountain Biopharma Inc Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Fountain Biopharma Inc T Cell Surface Glycoprotein CD4 Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Fountain Biopharma Inc T Cell Surface Glycoprotein CD4 Products Offered
      • 11.4.5 Fountain Biopharma Inc Recent Development
    • 11.5 Immupharma Plc
      • 11.5.1 Immupharma Plc Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Immupharma Plc T Cell Surface Glycoprotein CD4 Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Immupharma Plc T Cell Surface Glycoprotein CD4 Products Offered
      • 11.5.5 Immupharma Plc Recent Development
    • 11.6 Sanofi
      • 11.6.1 Sanofi Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Sanofi T Cell Surface Glycoprotein CD4 Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Sanofi T Cell Surface Glycoprotein CD4 Products Offered
      • 11.6.5 Sanofi Recent Development
    • 11.7 TaiMed Biologics Inc
      • 11.7.1 TaiMed Biologics Inc Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 TaiMed Biologics Inc T Cell Surface Glycoprotein CD4 Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 TaiMed Biologics Inc T Cell Surface Glycoprotein CD4 Products Offered
      • 11.7.5 TaiMed Biologics Inc Recent Development
    • 11.8 United Biomedical Inc
      • 11.8.1 United Biomedical Inc Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 United Biomedical Inc T Cell Surface Glycoprotein CD4 Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 United Biomedical Inc T Cell Surface Glycoprotein CD4 Products Offered
      • 11.8.5 United Biomedical Inc Recent Development

    12 Future Forecast

    • 12.1 T Cell Surface Glycoprotein CD4 Market Forecast by Regions
      • 12.1.1 Global T Cell Surface Glycoprotein CD4 Sales Forecast by Regions 2019-2025
      • 12.1.2 Global T Cell Surface Glycoprotein CD4 Revenue Forecast by Regions 2019-2025
    • 12.2 T Cell Surface Glycoprotein CD4 Market Forecast by Product
      • 12.2.1 Global T Cell Surface Glycoprotein CD4 Sales Forecast by Product 2019-2025
      • 12.2.2 Global T Cell Surface Glycoprotein CD4 Revenue Forecast by Product 2019-2025
    • 12.3 T Cell Surface Glycoprotein CD4 Market Forecast by End User
    • 12.4 North America T Cell Surface Glycoprotein CD4 Forecast
    • 12.5 Europe T Cell Surface Glycoprotein CD4 Forecast
    • 12.6 Asia Pacific T Cell Surface Glycoprotein CD4 Forecast
    • 12.7 Central & South America T Cell Surface Glycoprotein CD4 Forecast
    • 12.8 Middle East and Africa T Cell Surface Glycoprotein CD4 Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 T Cell Surface Glycoprotein CD4 Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global T Cell Surface Glycoprotein CD4 market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the T Cell Surface Glycoprotein CD4 market based on company, product type, end user and key regions.

      This report studies the global market size of T Cell Surface Glycoprotein CD4 in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of T Cell Surface Glycoprotein CD4 in these regions.
      This research report categorizes the global T Cell Surface Glycoprotein CD4 market by top players/brands, region, type and end user. This report also studies the global T Cell Surface Glycoprotein CD4 market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Biotest AG
      Bristol-Myers Squibb Co
      CEL-SCI Corp
      Fountain Biopharma Inc
      Immupharma Plc
      Sanofi
      TaiMed Biologics Inc
      United Biomedical Inc

      Market size by Product
      Forigerimod Acetate
      HIV Vaccine 2
      Ibalizumab
      Others
      Market size by End User
      HIV
      AIDS
      GVHD
      SARS
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global T Cell Surface Glycoprotein CD4 market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of T Cell Surface Glycoprotein CD4 market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global T Cell Surface Glycoprotein CD4 companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of T Cell Surface Glycoprotein CD4 submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of T Cell Surface Glycoprotein CD4 are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of T Cell Surface Glycoprotein CD4 market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now